Following systemic administration in chronic pancreatitis murine models, engineered biohybrid nanocarriers demonstrated multifunctional therapeutic outcomes, including elevation of somatostatin bioavailability in circulatory and pancreatic compartments, suppression of fibro-inflammatory mediators (TGF-β1, IL-6), and attenuation of histopathological damage indices. The gene discussed is SST; the disease is chronic pancreatitis.